title: How far is noninvasive assessment of liver fibrosis from replacing liver biopsy in hepatitis C?
abstract: Chronic hepatitis C represents a major cause of progressive liver disease that can eventually evolve into cirrhosis and its end-stage complications. Formation and accumulation of fibrosis in the liver is the common pathway that leads to evolutive liver disease. Precise staging of liver fibrosis is essential for patient management in clinical practice because the presence of bridging fibrosis represents a strong indication for antiviral therapy, while cirrhosis requires a specific follow-up. Liver biopsy has always represented the standard of reference for assessment of hepatic fibrosis, but it has limitations: it is invasive, costly and prone to sampling errors. Recently, blood markers and instrumental methods have been proposed for the noninvasive assessment of liver fibrosis in hepatitis C. However, international guidelines do not recommend the widespread use of noninvasive methods for liver fibrosis in clinical practice. This is because of, in some cases, unsatisfactory accuracy and incomplete validation of others. Some studies suggest that the effectiveness of noninvasive methods for assessing liver fibrosis may increase when they are combined, and a number of sequential and synchronous algorithms have been proposed for this purpose, with the aim of reducing rather than substituting liver biopsies. This may represent a rational and reliable approach for implementing noninvasive assessment of liver fibrosis in clinical practice. It could allow more comprehensive first-line screening of liver fibrosis in hepatitis C than would be feasible with liver biopsy alone.
authors.affiliation: VIMM-Venetian Institute of Molecular Medicine, Padua, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Sebastiani
authors.forename: A
authors.initials: A
authors.lastname: Alberti
mesh_terms: D000465:Algorithms; D015415:Biomarkers / Q000097:blood*; D001706:Biopsy; D054459:Elasticity Imaging Techniques / Q000295:instrumentation / Q000379:methods*; D016174:Hepacivirus; D019698:Hepatitis C, Chronic / Q000150:complications* / Q000473:pathology; D006801:Humans; D008099:Liver / Q000473:pathology*; D008103:Liver Cirrhosis / Q000097:blood / Q000473:pathology*; D017410:Practice Guidelines as Topic
chemical_list: D015415:Biomarkers